In 2007, the term NMOSD was introduced to include anti-AQP4 antibody-positive patients with limited or inaugural forms of NMO (e.g., first-attack longitudinally extensive transverse myelitis (LETM) or recurrent or bilateral optic neuritis) who were at high risk for future attacks [7]. The gene discussed is AQP4; the disease is optic neuritis.